Tumor necrosis factor alpha (TNF-alpha) promotes inflammatory responses, which, in turn, contribute to the clinical problems associated with many inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and refractory asthma. These diseases are sometimes treated with TNF-alpha inhibitors, including infliximab, adalimumab, etanercept, certolizumab pegol or golimumab. Prolonged therapies with these TNF-alpha inhibitors may lead to development of neutralizing antibodies (NAbs), which may counteract the TNF-alpha antagonist activity of the drugs.
0.2 mL of iLite® Reagent BLANK containing RPMI 1640 with 30% heat inactivated fetal bovine serum (FBS).
本公司网站所展示销售的产品仅供科研!
沪公网安备 31011202007337号